PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025

Reuters

2025/11/10

PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025

PDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute $(NCI)$ Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582743618"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582743618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582743618?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582743618","market":"us","top_or_hot":-1,"title":"PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PDSB\">PDS Biotechnology Corporation</a> has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute <a href=\"https://laohu8.com/S/NCI\">$(NCI)$</a> Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PDSB\">PDS Biotechnology Corporation</a> has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute <a href=\"https://laohu8.com/S/NCI\">$(NCI)$</a> Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL73hfZ1:1","article_id":"2582743618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582743618","pubTimestamp":1762781805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer  Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute  Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PDSB":"PDS Biotechnology Corporation"},"translate_title":"PDS Biotechnology在SITC 2025上报告PDS0101和PDS01ADC的阳性临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PDSB":0.9},"content_text":"PDS Biotechnology Reports Positive Clinical Data for PDS0101 and PDS01ADC at SITC 2025\n    \n\nPDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute $(NCI)$ Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}